ALT Altimmune Inc

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023

GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Chairman and Co-Founder, Pinnacle Clinical Research and Summit Clinical Research, will deliver an oral presentation of the results of Altimmune’s recently completed 12-week Phase 1b and 12-week extension trials of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) at the NASH-TAG Conference, which will be held in Park City, UT on January 6-7, 2023. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows:

Title:Pemvidutide, a Balanced GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Non-invasive Markers of Fibroinflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: Results of a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Presenter:Stephen Harrison, M.D., Chairman and Co-Founder of Pinnacle Clinical Research and Summit Clinical Research in San Antonio, TX
Date/Time:Saturday, January 7, 2023, at 10:30 am Mountain Standard Time

A copy of the presentation will be accessible on the section of the Altimmune website.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Investor & Media Contacts:

Richard Eisenstadt

Chief Financial Officer

Phone: 240-654-1450



EN
04/01/2023

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Result...

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s ...

21h / 50m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Closing of $75 Million Registered Direct Offering ...

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. Th...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Pricing of $75 Million Registered Direct Offering ...

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross procee...

January 28, 2026 1 EN
Free Trial
ALT ALTIMMUNE INC

Altimmune Inc: 1 director

A director at Altimmune Inc bought 5,000 shares at 4.082USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

01/09/26 January 9, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutid...

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of pa...

January 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch